thalidomide has been researched along with Hemorrhage in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| " 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13." | 7.91 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. ( Botella, LM; Buscarini, E; Dupuis-Girod, S; Geisthoff, U; Kjeldsen, AD; Mager, HJ; Pagella, F; Shovlin, CL; Suppressa, P; Zarrabeitia, R, 2019) |
| "Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)." | 7.74 | Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008) |
| "Deep venous thrombosis (DVT) is a common complication of thalidomide treatment." | 7.73 | Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. ( Baumann, MA; Ikhlaque, N; Kathula, S; Seshadri, V, 2006) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "Our findings revealed a key role for EGFL6 in SBVM pathogenesis and provided a mechanism explaining why thalidomide can cure small bowel bleeding resulting from SBVM." | 3.96 | Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation. ( Gao, YJ; Ge, ZZ; Liang, Q; Lin, XL; Tang, CT; Tang, MY; Wu, S; Zhang, QW, 2020) |
| " 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13." | 3.91 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. ( Botella, LM; Buscarini, E; Dupuis-Girod, S; Geisthoff, U; Kjeldsen, AD; Mager, HJ; Pagella, F; Shovlin, CL; Suppressa, P; Zarrabeitia, R, 2019) |
| " Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)." | 3.79 | Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013) |
| "Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)." | 3.74 | Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008) |
| "Deep venous thrombosis (DVT) is a common complication of thalidomide treatment." | 3.73 | Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. ( Baumann, MA; Ikhlaque, N; Kathula, S; Seshadri, V, 2006) |
| "Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG." | 1.43 | Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. ( Brophy, TM; Browne, PV; Hayden, PJ; Lavin, M; O'Connell, N; O'Donnell, JS; O'Sullivan, JM; Rawley, O; Ryan, K, 2016) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | 1.33 | Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Y | 1 |
| Chen, Q | 1 |
| Chen, L | 1 |
| Shen, SGF | 1 |
| Dai, J | 1 |
| Tang, CT | 1 |
| Zhang, QW | 1 |
| Wu, S | 1 |
| Tang, MY | 1 |
| Liang, Q | 1 |
| Lin, XL | 1 |
| Gao, YJ | 1 |
| Ge, ZZ | 1 |
| Cornell, RF | 1 |
| Goldhaber, SZ | 1 |
| Engelhardt, BG | 1 |
| Moslehi, J | 1 |
| Jagasia, M | 1 |
| Harrell, S | 1 |
| Rubinstein, SM | 1 |
| Hall, R | 1 |
| Wyatt, H | 1 |
| Piazza, G | 1 |
| Dodillet, H | 1 |
| Kreuzer, KA | 1 |
| Monsef, I | 1 |
| Skoetz, N | 1 |
| Storrar, NPF | 1 |
| Mathur, A | 1 |
| Johnson, PRE | 1 |
| Roddie, PH | 1 |
| Buscarini, E | 1 |
| Botella, LM | 1 |
| Geisthoff, U | 1 |
| Kjeldsen, AD | 1 |
| Mager, HJ | 1 |
| Pagella, F | 1 |
| Suppressa, P | 1 |
| Zarrabeitia, R | 1 |
| Dupuis-Girod, S | 1 |
| Shovlin, CL | 1 |
| Zitomersky, NL | 1 |
| Levine, AE | 1 |
| Atkinson, BJ | 1 |
| Harney, KM | 1 |
| Verhave, M | 1 |
| Bousvaros, A | 1 |
| Lightdale, JR | 1 |
| Trenor, CC | 1 |
| Sakai, M | 2 |
| Kubota, T | 2 |
| Takaoka, M | 1 |
| Tsukuda, T | 1 |
| Arakawa, Y | 1 |
| Anabuki, K | 1 |
| Ikezoe, T | 2 |
| Togitani, K | 1 |
| Yokoyama, A | 2 |
| Lavin, M | 1 |
| Brophy, TM | 1 |
| Rawley, O | 1 |
| O'Sullivan, JM | 1 |
| Hayden, PJ | 1 |
| Browne, PV | 1 |
| Ryan, K | 1 |
| O'Connell, N | 1 |
| O'Donnell, JS | 1 |
| Ouyang, HY | 1 |
| Yu, ZJ | 1 |
| Yin, J | 1 |
| Zhao, XJ | 1 |
| Wang, ZY | 1 |
| Zhang, W | 1 |
| Ma, ZN | 1 |
| Su, J | 1 |
| Bai, X | 1 |
| Ruan, CG | 1 |
| Eby, C | 1 |
| Palumbo, A | 1 |
| Cavo, M | 1 |
| Bringhen, S | 1 |
| Zamagni, E | 1 |
| Romano, A | 1 |
| Patriarca, F | 1 |
| Rossi, D | 1 |
| Gentilini, F | 1 |
| Crippa, C | 1 |
| Galli, M | 1 |
| Nozzoli, C | 1 |
| Ria, R | 1 |
| Marasca, R | 1 |
| Montefusco, V | 1 |
| Baldini, L | 1 |
| Elice, F | 2 |
| Callea, V | 1 |
| Pulini, S | 1 |
| Carella, AM | 1 |
| Zambello, R | 1 |
| Benevolo, G | 1 |
| Magarotto, V | 1 |
| Tacchetti, P | 1 |
| Pescosta, N | 1 |
| Cellini, C | 1 |
| Polloni, C | 1 |
| Evangelista, A | 1 |
| Caravita, T | 1 |
| Morabito, F | 1 |
| Offidani, M | 1 |
| Tosi, P | 1 |
| Boccadoro, M | 1 |
| Kuwayama, Y | 1 |
| Oshima, Y | 1 |
| Tojo, A | 1 |
| Moore, TJ | 1 |
| Bennett, CL | 1 |
| Lima, V | 1 |
| Brito, GA | 2 |
| Cunha, FQ | 1 |
| Rebouças, CG | 1 |
| Falcão, BA | 1 |
| Augusto, RF | 1 |
| Souza, ML | 1 |
| Leitão, BT | 1 |
| Ribeiro, RA | 2 |
| Ikhlaque, N | 1 |
| Seshadri, V | 1 |
| Kathula, S | 1 |
| Baumann, MA | 1 |
| Zangari, M | 1 |
| Fink, L | 1 |
| Tricot, G | 1 |
| Macedo, FY | 1 |
| Baltazar, F | 1 |
| Almeida, PR | 1 |
| Távora, F | 1 |
| Ferreira, FV | 1 |
| Schmitt, FC | 1 |
| Petter, C | 1 |
| Palmer, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for thalidomide and Hemorrhage
| Article | Year |
|---|---|
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines | 2017 |
[Acquired von Willebrand syndrome in three patients and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hemorrhage; Humans; Immunoglobulins, I | 2016 |
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
Topics: Blood Coagulation Disorders; Blood Platelet Disorders; Boronic Acids; Bortezomib; Hemorrhage; Humans | 2009 |
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR).
Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Thalidomide; Thrombosis; T | 2012 |
Thrombosis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Cytokines | 2007 |
2 trials available for thalidomide and Hemorrhage
| Article | Year |
|---|---|
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm | 2020 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
14 other studies available for thalidomide and Hemorrhage
| Article | Year |
|---|---|
Thalidomide leads to mandible hypoplasia through inhibiting angiogenesis and secondary hemorrhage in the fetal craniofacial region in rabbits.
Topics: Animals; Craniofacial Abnormalities; Down-Regulation; Female; Hemorrhage; Mandible; Maxillofacial Ab | 2020 |
Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation.
Topics: Angiogenesis Inhibitors; Animals; Calcium-Binding Proteins; Cell Adhesion Molecules; Cycloheximide; | 2020 |
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dise | 2019 |
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
Topics: Adolescent; Adult; Bevacizumab; Epistaxis; Female; Hemorrhage; Humans; Male; Retrospective Studies; | 2019 |
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli | 2013 |
Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
Topics: Hemorrhage; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Alveoli; Thalidomid | 2015 |
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Hemorrhage; Humans; Lenalidomide; Male; Middle A | 2016 |
Diffuse alveolar hemorrhage associated with lenalidomide.
Topics: Aged; Antineoplastic Agents; Hemorrhage; Humans; Lenalidomide; Male; Multiple Myeloma; Pulmonary Alv | 2011 |
Pulmonary alveolar hemorrhage possibly associated with lenalidomide use.
Topics: Antineoplastic Agents; Hemorrhage; Humans; Male; Pulmonary Alveoli; Thalidomide | 2011 |
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe | 2005 |
Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Cohort Studies; Female; Hem | 2006 |
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; Drug Therapy, Combination; Etorico | 2008 |
Early foetal thrombosis induced by thalidomide in mouse: possible explanation for teratogenicity.
Topics: Animals; Extremities; Female; Fetal Diseases; Hemorrhage; Mice; Mice, Inbred C57BL; Pregnancy; Thali | 1977 |
Sporadic malformations in laboratory animals and their influence on drug testing.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Laboratory; Aspirin; Bone and Bones; Congenital Abnor | 1972 |